Mirum (MIRM) president sells 16,515 shares, exercises 30,220 RSUs

Rhea-AI Filing Summary

Mirum Pharmaceuticals president and COO Peter Radovich reported a combination of equity award vesting and share sales. He exercised performance restricted stock units into 30,220 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.

On the following day, he sold 16,515 common shares at an average price of $91.9779 per share, with a footnote stating the sale was to cover tax withholding obligations from the RSU vesting. After these transactions, he directly holds 40,272 common shares and continues to hold 11,500 performance restricted stock units scheduled to vest over future dates.

Insights

Equity compensation and insider-trading analyst

Routine equity award vesting with tax-related share sale, minimal signal.

Peter Radovich, president and COO of Mirum Pharmaceuticals, exercised performance restricted stock units into 30,220 common shares at a conversion price of $0.00. This reflects standard equity compensation vesting rather than an open-market purchase.

He then sold 16,515 shares of common stock at $91.9779 per share on March 16, 2026. A footnote states these shares were sold to satisfy tax withholding obligations tied to the RSU vesting, a mechanistic transaction with weak informational value about his view of the stock.

Following these moves, Radovich directly owns 40,272 common shares and retains 11,500 performance restricted stock units that vest in tranches on March 15, 2026 and March 15, 2027. Overall, this filing shows routine compensation events rather than a thesis-changing insider trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND COO

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		7,220	A	(1)	33,787	D
Common Stock	03/15/2026		M		23,000	A	(1)	56,787	D
Common Stock	03/16/2026		S(2)		16,515	D	$91.9779	40,272	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Restricted Stock Units	(1)	03/15/2026		M			7,220	(3)	(3)	Common Stock	7,220	$0	0	D
Performance Restricted Stock Units	(1)	03/15/2026		M			23,000	(4)	(4)	Common Stock	23,000	$0	11,500	D

Explanation of Responses:

1. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.

3. The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.

4. The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mirum (MIRM) president Peter Radovich report?

Peter Radovich reported exercising performance restricted stock units into 30,220 shares of Mirum common stock and selling 16,515 shares. The sale occurred at an average price of $91.9779 per share and was linked to tax withholding obligations from the RSU vesting.

Was the Mirum (MIRM) insider share sale a discretionary sale or tax-related?

The sale was tax-related. A footnote explains that the 16,515 shares of Mirum common stock sold by Peter Radovich were used to cover tax withholding obligations associated with the vesting of his performance restricted stock units, indicating a mechanistic rather than discretionary sale.

How many Mirum (MIRM) shares does Peter Radovich hold after these transactions?

After the reported transactions, Peter Radovich directly holds 40,272 shares of Mirum common stock. In addition, one RSU grant entry shows 11,500 performance restricted stock units remaining outstanding, which are scheduled to vest over future dates according to the disclosed vesting schedules.

What price did Mirum (MIRM) insider Peter Radovich receive for the shares sold?

Peter Radovich sold 16,515 shares of Mirum common stock at an average price of $91.9779 per share. These shares were sold specifically to satisfy tax withholding obligations related to the vesting of performance restricted stock units, as described in the filing footnotes.

How many Mirum (MIRM) performance RSUs did Peter Radovich exercise?

He exercised performance restricted stock units covering 30,220 underlying shares of Mirum common stock. The RSUs converted at a price of $0.00 per share, reflecting equity compensation vesting rather than a cash purchase in the open market by the executive.

Do any Mirum (MIRM) performance RSUs remain outstanding for Peter Radovich?

Yes. One of the performance restricted stock unit awards shows 11,500 units remaining outstanding after the exercises. Footnotes state the related shares vest in tranches on March 15, 2026 and March 15, 2027, providing future potential share delivery.